Primary Peritoneal

Treatment Stage Short Name Protocol Title ClinicalTrials.Gov Link Penn Research Coordinator Am I Eligible?
Stage II-IV Newly Diagnosed  GY019 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum


Christine Yang 

Eligibility Criteria 
Any Penn Legacy Tissue Program Participation in the Ovarian Cancer Research Center Rapid Autopsy Program N/A Dalia Omran Eligibility Criteria 
Recurrent  CAPRI CAPRI: Combination ATR and PARP Inhibitor (CAPRI) Trial with AZD6738 and Olaparib in Recurrent Ovarian Cancer NCT03462342 Shavon Rochester Eligibility Criteria 
Recurrent MYTHIC Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients with Advanced Solid Tumors (MYTHIC Study) NCT04855656 Andrea Standish, RN  Eligibility Criteria
Recurrent MAGNETIC Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study) NCT05147272 Andrea Standish, RN Eligibility Criteria
Recurrent  STRO+bev

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody DrugConjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)

NCT05200364 Christine Yang  Eligibility Criteria 
Recurrent FAETH A Phase 1b Study of Serabelisib in Combination with an Insulin Suppressing Diet (Study ISD) in Subjects with Advanced Solid Tumors with PIK3CA Mutations with or without PTEN loss NCT05300048 Katie Elkins Eligibility Criteria
Recurrent ATRIN A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral ATRN-119 in Patients with Advanced Solid Tumors NCT04905914 Andrea Standish, RN  Eligibility Criteria
Recurrent Xencor A Phase 2 Study of XmAb®20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer NCT05032040 Isabel Forbes Eligibility Criteria
Recurrent GOG 3049 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Upifitamab Rilsodotin as Post-Platinum Maintenance Therapy for Participants with Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) NCT05329545 Kristina Powell Eligibility Criteria
Recurrent GOG 3066 A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT04814108 Kristina Powell Eligibility Criteria 
Recurrent GOG 3063 A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7) NCT05092360 Shavon Rochester Eligibility Criteria
Recurrent STAR-101 A Phase 1 Study of SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR, in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma NCT05568680 Katie Elkins Eligibility Criteria
Recurrent NP-G2-044-P2-01 NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies NCT05023486 Shavon Rochester Eligibility Criteria